Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Won’t Go Hollywood: In-House R&D Still Focus As Outside Deals Expand

Executive Summary

Merck is on a pace to sign 50 outside R&D alliances during 2003
Advertisement

Related Content

Merck Drops Strict “No Merger” Policy, But Still Prefers Licensing Deals
Lilly Sees Value In Biotech R&D, Will Focus On Partnerships Over Acquisitions
Schering Says Smaller Is Better: Flexibility Aids Turnaround Process
Democracy In Action: Biotech Access To R&D Tools Spurs Licensing Deals
Levitra Is Big News On Wall Street, But Rx Firms Ask Investors To Think Small
Levitra Is Big News On Wall Street, But Rx Firms Ask Investors To Think Small
Merck Buys Out Banyu; Will Bring “Global Perspective” To Japanese R&D
Merck Completes R&D Leadership Transition To Kim; Spotlight On Genomics
Merck/Rosetta Scales Up Merck's Genomics Effort, Merger Comfort Level?
Merck/Rosetta Scales Up Merck's Genomics Effort, Merger Comfort Level?
Advertisement
UsernamePublicRestriction

Register

PS042618

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel